Novartis, Galvus European approval as new treatment for type 2 diabetes

September 28, 2007 - Galvus (vildagliptin), a new once-daily oral treatment for patients with type 2 diabetes, has been granted European Union approval. Galvus is the only drug in its class to offer such a broad range of indications for use in combination therapies with other anti-diabetic medicines... Novartis' Press Release -